Gali Weinreb

Israel

Biomed Correspondent at Globes

Featured in: Favicon

globes.co.il Favicon

jpost.com

albawaba.com Favicon

mondaq.com Favicon

msn.com

pharmaceuticalintelligence.com Favicon

flipboard.com Favicon

en.globes.co.il

Articles

PolyPid reports positive phase 3 surgical infection drug trial

2 weeks ago | en.globes.co.il | Dikla Czaczkes Akselbrad |Gali Weinreb

The Israeli company's treatment is a delayed-release antibiotic administered in the area where the patient has undergone surgery. Israeli late-stage biopharmaceutical company PolyPid (Nasdaq: PYPD) has reported positive Phase III trial results on its treatment for surgical infections. In 2022, PolyPid's previous trial of the drug failed, which saw its share price fall 77% in one day and continue falling since. Yesterday the share price rose 2.75%, giving a market cap of $34.24 million.
Teva gives aggressive guidance for innovative drugs

1 month ago | en.globes.co.il | Richard Francis |Gali Weinreb

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) held an "Innovation and Strategy Day" today, in which it discussed the future of its (non-generic) biopharmaceutical activity. The company sees revenue from its three leading drugs: Austedo, for treating involuntary movements; migraine prevention treatment Ajovy; and long-acting schizophrenia treatment Uzedy, reaching at least $5 billion by 2030. This compares with $2 billion for the three products combined in 2024.
"I expected a million; we received $125m"

1 month ago | en.globes.co.il | Gali Weinreb

Israeli universities do not generally disclose the lists of their donors and how much they have raised, but in the past year three of them boasted especially high contributions. The latest was Tel Aviv University.
Calls to exclude Israel from Horizon jeopardize research

1 month ago | en.globes.co.il | Gali Weinreb

Apartments sold and rented Israel claims Sanaa Airport out of action With the EU discussing proposals to end Israel's participation in the Horizon program, and the Trump administration cutting international grants, Israeli researchers fear for the future. Israel's exclusion from the EU's Horizon Europe research and innovation program and its support for science, as is being discussed, would set Israeli science back years and relegate its status.
Israeli companies streamlining US healthcare

1 month ago | en.globes.co.il | Gali Weinreb

Is Nice ready to bounce back? Iron Beam - world's most powerful laser defense system Over the past 15 years, Israeli startups have been applying Big Data to cure the US healthcare system’s ills. How do they do it, and can they maintain their advantage? Israel’s biomedical industry is undergoing among its most difficult periods, but two sub-sectors are still managing to keep their heads above water.
Qiagen buys Israeli AI software co Genoox

1 month ago | en.globes.co.il | Gali Weinreb

US diagnostics giant Qiagen has announced that it has signed a definitive agreement to acquire Israeli AI software company Genoox for $80 million, including an immediate payment of $70 million and a further $10 million in milestone payments. Genoox, which has 55 employees, will become Qiagen's Israel development center and will expand by hiring more development and software staff.
Tel Aviv University medical school receives $125m donation

1 month ago | en.globes.co.il | Gali Weinreb

Israel the loser from US-Houthi truce Tel Aviv slips in World's Wealthiest Cities ranking The donation, from Blackstone president Jon Gray and his wife Mindy, will enable the university's Faculty of Medical and Health Sciences to expand both in medical studies and research.
Prilenia signs deal for former Teva ALS drug worth up to €500m

2 months ago | en.globes.co.il | Gali Weinreb

Israeli-Dutch clinical stage biotech company Prilenia Therapeutics has announced a collaboration and licensing agreement for its lead drug Pridopidine, with Spanish pharmaceutical company Ferrer. As part of the agreement Prilenia will receive €125 million in immediate and near-term milestone payments and up to €500 million overall including all milestone payments as well as royalties if the product is improved and sales successfully on the market.
Astrazeneca sets up Tel Aviv center to study Israeli health data

2 months ago | en.globes.co.il | Gali Weinreb

How much are the Israeli digital medical data files of each patient, gathered over decades, worth to the world's leading pharmaceutical companies? Opinions on this subject are divided and change from time to time. Shortly before and during the Covid pandemic, the prevailing consensus was that databases gave the Israeli biomedical sector a huge advantage and were a factor that would attract the activities of leading companies here.
Food-tech co NextFerm suspends operations

2 months ago | en.globes.co.il | Gali Weinreb

Another Israeli company from the wave of tech flotations on the Tel Aviv Stock Exchange (TASE) in 2021 has reached the end of the road as an independent business. Food-tech company NextFerm Technologies Ltd. announced this week that it is suspending operations, except for a joint venture in India. Following the announcement, the company's share price plunged 50%, giving it a market cap of NIS 7 million, a fall of 99.5% since its IPO.